| Author | Piulats, Josep M. | |
| Author | Vidal, August | |
| Author | Rodríguez, Francisco J. García | |
| Author | Muñoz, Clara | |
| Author | Nadal, Marga | |
| Author | Moutinho, Catia | |
| Author | Iniesta, María Martínez | |
| Author | Mora, Josefina | |
| Author | Figueras, Agnés | |
| Author | Guinó, Elisabet | |
| Author | Padullés, Laura | |
| Author | Aytés, Àlvaro | |
| Author | Molleví, David G. | |
| Author | Puertas, Sara | |
| Author | Fernández, Carmen Martínez | |
| Author | Castillo, Wilmar | |
| Author | Juliachs, Merce | |
| Author | Moreno, Victor | |
| Author | Muñoz, Purificación | |
| Author | Stefanovic, Milica | |
| Author | Pujana, Miguel A. | |
| Author | Condom, Enric | |
| Author | Esteller, Manel | |
| Author | Germà, Josep R. | |
| Author | Capella, Gabriel | |
| Author | Farré, Maria de Lourdes Vallve | |
| Author | Morales, Albert | |
| Author | Viñals, Francesc | |
| Author | García-Del-Muro, Xavier | |
| Author | Cerón, Julián | |
| Author | Villanueva, Alberto | |
| Access date | 2019-02-18T13:54:49Z | |
| Available date | 2019-02-18T13:54:49Z | |
| Document date | 2018 | |
| Citation | PIULATS, J. M. et al. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clinical Cancer Research, v. 24, n. 15, p. 3755-3766, 2018. | pt_BR |
| ISSN | 1078-0432 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/31701 | |
| Description | Farré, Maria de Lourdes Vallve. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
1Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute
of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL),
Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
2Department of Medical Oncology, Catalan Institute of Oncology (IDIBELL),
Barcelona, Spain. 3Department of Pathology, Hospital Universitari de Bellvitge
(IDIBELL), CIBERONC, Barcelona, Spain. 4Xenopat S.L., Business Bioincubator,
Bellvitge Health Science Campus, L'Hospitalet de Llobregat, Barcelona, Spain.
5Cancer Epigenetics and Cell Biology Program (PEBC), Catalan Institute of
Oncology (IDIBELL), Barcelona, Spain. 6Department of Biochemistry, Hospital
de Sant Pau, Barcelona, Spain. 7Bioinformatic Unit, Catalan Institute of Oncology
(IDIBELL), Barcelona, Spain. 8Modelling Human Diseases in C. elegans. Genes,
Disease and Therapy Program (IDIBELL), Barcelona, Spain. 9Department of Cell
Death and Proliferation, Instituto de Investigaciones Biom edicas de Barcelona
(IIBB-CSIC), IDIBAPS, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
10Laboratory of Experimental Pathology (LAPEX), Gonçalo Moniz Research
Center, Oswaldo Cruz Foundation (CPQGM/FIOCRUZ), Salvador, Bahia, Brazil.
11Institute of Science and Technology of Tropical Diseases (INCT/DT), Salvador,
Brazil. 12Departament de Ciencies Fisiologiques II, Universitat de Barcelona,
L'Hospitalet de Llobregat, Barcelona, Spain. 13C. elegans Core Facilty-IDIBELL,
Barcelona, Spain. | pt_BR |
| Sponsorship | Spanish Ministry of Economy and Competitiveness (SAF2002-02265 and
FIS: BFU2007-67123; PI10-0222, PI13-01339, and PI16/01898, to A. Villanueva;
PI15-00895, to J. Cer on; SAF2013-46063R, to F. Vi~nals; PI030264, to
X. García-del-Muro), Fundaci o La Marat o TV3 (051430, to F. Vi~nals and X.
García-del-Muro), Generalitat de Catalunya (2014SGR364, to A. Villanueva
and F. Vinals; FIS09/0059, to A. Morales), cofunded by FEDER funds/
European Regional Development Fund (ERDF) — a way to Build Europe.
A. Villanueva received a BAE11/00073 grant. We thank the staff of the
Animal Core Facility of IDIBELL for mouse care and maintenance. | pt_BR |
| Language | eng | pt_BR |
| Publisher | American Association for Cancer Research | pt_BR |
| Rights | restricted access | pt_BR |
| Subject in Portuguese | Tumores | pt_BR |
| Subject in Portuguese | Neoplasias testiculares | pt_BR |
| Subject in Portuguese | Glicosilceramida | pt_BR |
| Subject in Portuguese | Resistência a drogas | pt_BR |
| Subject in Portuguese | Quimioterapia | pt_BR |
| Subject in Portuguese | Células germinativas | pt_BR |
| Subject in Portuguese | Animais | pt_BR |
| Title | Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent | pt_BR |
| Type | Article | |
| DOI | 10.1158/1078-0432.CCR-17-1898 | |
| Abstract | Purpose: To investigate the genetic basis of cisplatin resistance as efficacy of cisplatin-based chemotherapy in the treatment of distinct malignancies is often hampered by intrinsic or acquired drug resistance of tumor cells.Experimental Design: We produced 14 orthoxenograft transplanting human nonseminomatous testicular germ cell tumors (TGCT) in mice, keeping the primary tumor features in terms of genotype, phenotype, and sensitivity to cisplatin. Chromosomal and genetic alterations were evaluated in matched cisplatin-sensitive and their counterpart orthoxenografts that developed resistance to cisplatin in nude mice.Results: Comparative genomic hybridization analyses of four matched orthoxenografts identified recurrent chromosomal rearrangements across cisplatin-resistant tumors in three of them, showing gains at 9q32-q33.1 region. We found a clinical correlation between the presence of 9q32-q33.1 gains in cisplatin-refractory patients and poorer overall survival (OS) in metastatic germ cell tumors. We studied the expression profile of the 60 genes located at that genomic region. POLE3 and AKNA were the only two genes deregulated in resistant tumors harboring the 9q32-q33.1 gain. Moreover, other four genes (GCS, ZNF883, CTR1, and FLJ31713) were deregulated in all five resistant tumors independently of the 9q32-q33.1 amplification. RT-PCRs in tumors and functional analyses in Caenorhabditis elegans (C. elegans) indicate that the influence of 9q32-q33.1 genes in cisplatin resistance can be driven by either up- or downregulation. We focused on glucosylceramide synthase (GCS) to demonstrate that the GCS inhibitor DL-threo-PDMP resensitizes cisplatin-resistant germline-derived orthoxenografts to cisplatin.Conclusions: Orthoxenografts can be used preclinically not only to test the efficiency of drugs but also to identify prognosis markers and gene alterations acting as drivers of the acquired cisplatin resistance. Clin Cancer Res; 24(15); 3755-66. ©2018 AACR. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. | pt_BR |
| Affilliation | Multipla - ver em Notas | pt_BR |
| Subject | Tumors | pt_BR |
| Subject | Testicular Neoplasms | pt_BR |
| Subject | Glucosylceramide | pt_BR |
| Subject | Drug Resistance | pt_BR |
| Subject | Chemotherapy | pt_BR |
| Subject | Germ Cells | pt_BR |
| Subject | Animals | pt_BR |
